Výsledky vyhledávání - Keith Dredge
- Zobrazuji výsledky 1 - 20 z 20
-
1
-
2
-
3
-
4
-
5
-
6
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity Autor Keith Dredge, J B Marriott, Stephen Todryk, George W. Muller, Roger Chen, David Stirling, Angus Dalgleish
Vydáno 2002Artigo -
7
PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer Autor Katherine T. Ostapoff, Niranjan Awasthi, Bercin Kutluk Cenik, Stefan Hinz, Keith Dredge, Roderich E. Schwarz, Rolf A. Brekken
Vydáno 2013Artigo -
8
-
9
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models Autor Keith Dredge, Edward Hammond, Paul Handley, Thomas J. Gonda, Maree T. Smith, Christina Vincent, Ralf Brandt, Vito Ferro, Ian Bytheway
Vydáno 2011Artigo -
10
-
11
-
12
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors Autor Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang, Keith Dredge
Vydáno 2018Artigo -
13
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced... Autor J. Blake Bartlett, A Michael, Ian Clarke, Keith Dredge, Steve Nicholson, Hartmut Kristeleit, A. Polychronis, H. Pandha, George W. Muller, David Stirling, Jerome B. Zeldis, Angus Dalgleish
Vydáno 2004Artigo -
14
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours Autor Keith Dredge, Todd V. Brennan, Edward Hammond, Jason D. Lickliter, Liwen Lin, Darryn Bampton, Paul Handley, Fleur Lankesheer, Glynn Morrish, Yiping Yang, Michael P. Brown, Michael Millward
Vydáno 2018Artigo -
15
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine Autor Deok-Beom Jung, Miyong Yun, Eun-Ok Kim, Jaekwang Kim, Bonglee Kim, Ji Hoon Jung, Enfeng Wang, Debabrata Mukhopadhyay, Edward Hammond, Keith Dredge, Viji Shridhar, Sung‐Hoon Kim
Vydáno 2014Artigo -
16
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Autor Christine Galustian, B Meyer, Marie‐Christine Labarthe, Keith Dredge, Deborah Klaschka, Jake Y. Henry, Stephen Todryk, Roger Chen, George W. Muller, David Stirling, Peter Schäfer, J. Blake Bartlett, Angus Dalgleish
Vydáno 2008Artigo -
17
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... Autor Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew D. Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque, Grace Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein
Vydáno 2023Artigo -
18
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples Autor Boris Winterhoff, Luisa Freyer, Edward Hammond, Shailendra Giri, Susmita Mondal, Debarshi Roy, Attila Teoman, Sally A. Mullany, Robert Hoffmann, Antonia von Bismarck, Jeremy Chien, Matthew S. Block, Michael Millward, Darryn Bampton, Keith Dredge, Viji Shridhar
Vydáno 2015Artigo -
19
HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer Autor Susmita Mondal, Debarshi Roy, Juliana Camacho-Pereira, Ashwani Khurana, Eduardo N. Chini, Lifeng Yang, Joelle Baddour, Katherine Stilles, Seth Padmabandu, Sam Leung, Steve E. Kalloger, C. Blake Gilks, Val J. Lowe, Thomas Dierks, Edward Hammond, Keith Dredge, Deepak Nagrath, Viji Shridhar
Vydáno 2015Artigo -
20
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction Autor Scott E. Guimond, Courtney J. Mycroft‐West, Neha S. Gandhi, Julia A. Tree, Thuy T. Le, C. Mirella Spalluto, María Victoria Humbert, Karen R. Buttigieg, Naomi S. Coombes, Michael J. Elmore, Matthew E. Wand, Kristina Nyström, Joanna Said, Yin Xiang Setoh, Alberto A. Amarilla, Naphak Modhiran, Julian D. J. Sng, Mohit Chhabra, Paul R. Young, Daniel J. Rawle, Marcelo A. Lima, Edwin A. Yates, Richard Karlsson, Rebecca L. Miller, Yen‐Hsi Chen, Ieva Bagdonaite, Zhang Yang, James P. Stewart, Dung Nguyen, Stephen M. Laidlaw, Edward Hammond, Keith Dredge, Tom Wilkinson, Daniel Watterson, Alexander A. Khromykh, Andreas Suhrbier, Miles W. Carroll, Edward Trybala, Tomas Bergström, Vito Ferro, Mark A. Skidmore, Jeremy E. Turnbull
Vydáno 2022Artigo
Vyhledávací nástroje:
Související témata
Medicine
Biology
Cancer research
Internal medicine
Biochemistry
Cancer
Chemistry
Immunology
Angiogenesis
Heparan sulfate
Heparanase
Immune system
In vitro
Metastasis
Pharmacology
Biotechnology
Cell biology
Genetics
In vivo
Multiple myeloma
Oncology
Tumor microenvironment
Adverse effect
Cytotoxic T cell
Heparin
Pancreatic cancer
T cell
Thalidomide
Biological activity
CD8